KR100880061B1 - 이반드로네이트의 제조 방법 - Google Patents

이반드로네이트의 제조 방법 Download PDF

Info

Publication number
KR100880061B1
KR100880061B1 KR1020077011938A KR20077011938A KR100880061B1 KR 100880061 B1 KR100880061 B1 KR 100880061B1 KR 1020077011938 A KR1020077011938 A KR 1020077011938A KR 20077011938 A KR20077011938 A KR 20077011938A KR 100880061 B1 KR100880061 B1 KR 100880061B1
Authority
KR
South Korea
Prior art keywords
formula
methyl
ibandronate
carried out
pentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077011938A
Other languages
English (en)
Korean (ko)
Other versions
KR20070070246A (ko
Inventor
프리드리히 바에츠
베른트 중한스
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20070070246A publication Critical patent/KR20070070246A/ko
Application granted granted Critical
Publication of KR100880061B1 publication Critical patent/KR100880061B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020077011938A 2004-10-29 2005-10-25 이반드로네이트의 제조 방법 Expired - Fee Related KR100880061B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105407.3 2004-10-29
EP04105407 2004-10-29

Publications (2)

Publication Number Publication Date
KR20070070246A KR20070070246A (ko) 2007-07-03
KR100880061B1 true KR100880061B1 (ko) 2009-01-22

Family

ID=36097233

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011938A Expired - Fee Related KR100880061B1 (ko) 2004-10-29 2005-10-25 이반드로네이트의 제조 방법

Country Status (13)

Country Link
US (1) US7214818B2 (https=)
EP (1) EP1807090B9 (https=)
JP (1) JP4560548B2 (https=)
KR (1) KR100880061B1 (https=)
CN (1) CN101048165B (https=)
AT (1) ATE497769T1 (https=)
CA (1) CA2585027C (https=)
DE (1) DE602005026310D1 (https=)
ES (1) ES2359415T3 (https=)
IL (1) IL182690A (https=)
MX (1) MX2007005114A (https=)
TW (1) TWI293304B (https=)
WO (1) WO2006045578A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
ATE473990T1 (de) 2006-06-23 2010-07-15 Cipla Ltd Verfahren zur synthese von ibandronat-natrium
CA2656053A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
US20090012047A1 (en) * 2006-11-16 2009-01-08 Eran Turgeman Crystalline forms of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
SI2144919T1 (sl) * 2007-04-11 2016-02-29 F. Hoffmann-La Roche Ag Večstopenjska sinteza ibandronata
US20100125149A1 (en) * 2007-04-19 2010-05-20 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
US20090075944A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ibandronate
WO2009093258A2 (en) * 2008-01-24 2009-07-30 Fleming Laboratories Limited A new and improved process for the preparation of ibandronate sodium monohydrate
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
US20100130746A1 (en) * 2008-11-26 2010-05-27 Martin Kas Process for Making Zoledronic Acid
EP2192126B1 (en) 2008-11-26 2013-03-27 Synthon B.V. Process for making zoledronic acid
CN101863919B (zh) * 2010-07-05 2011-11-23 武汉同源药业有限公司 一种化合物伊班膦酸钠的制备方法
CN102093416B (zh) * 2011-03-17 2013-07-24 南京恒生制药有限公司 一种合成伊班膦酸钠的方法
CN103012155A (zh) * 2012-11-29 2013-04-03 张家港市大伟助剂有限公司 一种n-甲基戊胺的制备方法
CN103396332A (zh) * 2013-08-19 2013-11-20 四川协力制药有限公司 3—[（n—甲基—n—戊基）氨基]丙酸盐酸盐的制备方法
CN104628768A (zh) * 2015-03-06 2015-05-20 江苏正大清江制药有限公司 一种伊班膦酸钠的制备方法
CN114524925B (zh) * 2020-11-23 2023-11-14 华润化学材料科技股份有限公司 钛系催化剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919321A (en) * 1966-11-08 1975-11-11 Hoffmann La Roche Halo-substituted-5H-dibenzo{8 a,d{9 cyclohepten-5-ones
US4220611A (en) * 1978-06-29 1980-09-02 Sandoz, Inc. Polyoxyalkylene bridged phosphate esters
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3808074A1 (de) * 1988-03-11 1989-09-21 Henkel Kgaa Verfahren zur herstellung von azacycloalkan-2,2-diphosphonsaeuren
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
AU2003233569A1 (en) 2002-05-17 2003-12-02 Teva Pharmaceutical Industries Ltd. Use of certain diluents for making bisphosphonic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, 2002, vol. 45, no. 17, pp. 3721-3738

Also Published As

Publication number Publication date
CA2585027A1 (en) 2006-05-04
EP1807090B9 (en) 2011-11-09
TW200621792A (en) 2006-07-01
KR20070070246A (ko) 2007-07-03
JP2008517964A (ja) 2008-05-29
IL182690A (en) 2011-07-31
ATE497769T1 (de) 2011-02-15
IL182690A0 (en) 2007-09-20
MX2007005114A (es) 2007-06-26
US7214818B2 (en) 2007-05-08
TWI293304B (en) 2008-02-11
EP1807090A2 (en) 2007-07-18
DE602005026310D1 (de) 2011-03-24
US20060094898A1 (en) 2006-05-04
WO2006045578A3 (en) 2006-08-17
CA2585027C (en) 2010-05-18
ES2359415T3 (es) 2011-05-23
EP1807090B1 (en) 2011-02-09
WO2006045578A2 (en) 2006-05-04
JP4560548B2 (ja) 2010-10-13
CN101048165A (zh) 2007-10-03
CN101048165B (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
KR100880061B1 (ko) 이반드로네이트의 제조 방법
JP2008517964A5 (https=)
CN101111504B (zh) 伊班膦酸盐多晶型物a
CN101111505A (zh) 伊班膦酸盐多晶型物b
US7662990B2 (en) Process for preparing ibandronate
US20090281320A1 (en) Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof
NO176663B (no) Analogifremgangsmåte for fremstilling av terapeutisk anvendbare, aromatisk substituerte alkylaminoalkandifosfonsyrer
US7485726B2 (en) Process for the preparation of risedronate sodium hemi-pentahydrate
JP3547441B2 (ja) 製法
EP2038291B1 (en) Process for the synthesis of ibandronate sodium
CA2590046A1 (en) Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt
PL141981B1 (en) Process for preparing n-phosphonmethylglycine and its derivatives
JPH04305588A (ja) ホスホノオルガノカルボン酸の製造方法

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20131227

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20141230

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180116

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180116

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000